论文部分内容阅读
目的研究ERα阳性表达的乳腺癌组织中ERβ蛋白与C-erbB-2蛋白表达情况,探讨ERβ亚型表达的变化与内分泌治疗抵抗之间的关系,为乳腺癌临床内分泌治疗方案的确定提供更确切的理论依据。方法对83例乳腺癌患者,用免疫组化法检测组织中ERα的表达,同时检测ERα阳性组织中原癌蛋白C-erbB-2及ERβ表达的变化。结果48例ERα阳性的乳腺癌组织中,C-erbB-2表达阳性者,ERβ的表达量显著升高(P<0.001)。结论ERβ高表达与内分泌治疗的耐药表现有关,检测ERβ的表达水平可作为另一预测内分泌治疗效果的有用指标。
Objective To investigate the expression of ERβ protein and C-erbB-2 protein in ERα -positive breast cancer tissues and to explore the relationship between the changes of ERβ subtypes and the resistance of endocrine therapy, so as to provide a more accurate method for the determination of clinical endocrine therapy in breast cancer The theoretical basis. Methods The expression of ERα in the tissues of 83 cases of breast cancer was detected by immunohistochemistry. Meanwhile, the expression of C-erbB-2 and ERβ in ERα positive tissues was detected. Results The expression of ERβ was significantly increased in 48 cases of ERα positive breast cancer with positive expression of C-erbB-2 (P <0.001). Conclusion The high expression of ERβ is related to the drug resistance of endocrine therapy. Detecting the expression level of ERβ may be used as another useful index to predict the effect of endocrine therapy.